A Phase 2 interventional study of Brenipatide and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by Eli Lilly and Company. Recruiting at 127 sites in 18 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,279 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 138 open to participants now, 173 under way, 20 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.
Among the 1,279 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 201st largest by planned enrollment of the 1,038 interventional ones that give a count, is one of 40 that started in 2026, is one of 193 in phase 2, reaches primary completion later than 110 of the 172 other live ones, and was the 1,265th registered.
5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →138 of the 1,279 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 40–80
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
Enanta Pharmaceuticals, Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 117 · Phase 2 231 · Phase 3 238 · Phase 4 98
First in 1994; this study’s year is marked. 40 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 606 is above the median of 62 across 3,844 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 100 across the 1,038 interventional studies, 171 across the 237 observational. Of the 1,018 that completed or were terminated, 502 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
604 of 1,279 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 4 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
62 of the studies in Pulmonary Disease, Chronic Obstructive with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05265299Phase 3Johns Hopkins UniversityTrial to Determine Effective Aspirin Dose in COPD | 2026-12 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT05879211Duke UniversityGoal Concordant Care Learning Laboratory | 2026-12 |
Add all 62 to your calendar (.ics) → With an account.
Among the 1,279 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a physician diagnosis of (COPD), at least 12 months prior to screening who meet the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brenipatide low dose administered subcutaneously (SC) in combination with Standard of Care (SOC).
Drug: Brenipatide · Drug: Standard of Care
Brenipatide high dose administered SC in combination with SOC.
Drug: Brenipatide · Drug: Standard of Care
Placebo administered SC in combination with SOC.
Drug: Placebo · Drug: Standard of Care
Brenipatide administered SC
Also known as: LY3537031
Placebo administered SC
SOC
Change from Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁)
Time frame: Baseline through Week 36
Annualized Moderate or Severe COPD Exacerbation Rate Over 52 Weeks of Treatment
Time frame: Baseline through Week 52
Change from Baseline in St. George's Respiratory Questionnaire for COPD (SGRQ-C) Total Score
Time frame: Baseline, Week 36, and Week 52
Change from Baseline in Pre-BD FEV₁
Time frame: Baseline through Week 52
Showing the first 100 of 127 sites across 18 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for May 2028, 21 months after the start.
Of 119 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 21 months is above that.
Counting every sponsor, half of 166 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brenipatide
Pulmonary Disease, Chronic Obstructive →